Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Blood Pressure Optimisation in Polycystic Kidney Disease and Hypertension by Rotation Through Main Antihypertensive Drug Classes
2005-003182-16Phase 4Completed
- Sponsor
- Cambridge University Hospitals NHS Foundation Trust
- Start
- Jul 2005
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, single-arm trial of doxazosin, bisoprolol, lisinopril, amlodipine, candesartan and 1 more in polycystic kidney disease (PKD) and hypertension (HTN), sponsored by Cambridge University Hospitals NHS Foundation Trust. Primary endpoints: Fall in systolic blood pressure and Fall in diastolic blood pressure. Started Jul 2005; status: completed.
02
Drugs
doxazosinbisoprolollisinoprilamlodipinecandesartan
03
Conditions
polycystic kidney disease (PKD)hypertension (HTN)
Beyond the preview
Go deeper on 2005-003182-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-003182-16.